Trial population
T2DM
AMI
In the EMMY trial a total of 476 patients were successfully enrolled to either receive 10 mg Empagliflozin or placebo, a total of 374 patients (78,6%) with available frozen blood samples for all visits were included in the post-hoc analysis, 191 of them in the Empagliflozin group (51.1%) and 183 patients in the placebo group.Baseline characteristics were comparable between both groups with an overall mean age of 57.6 ± 9.0 years, a mean body mass index (BMI) of 28.2 ± 4.3 kg/m² and 18.5% female patients. Analysis of the cardiovascular risk factors showed T2DM in 13.7% of all patients, a mean systolic blood pressure of 126.5 ± 13.34mmHg, and a mean diastolic blood pressure of 79.8 ± 8.3mmHg. A blood pressure control of below 140/90mmHg was achieved in 302 patients (80.75%) at baseline and 227 patients (60.70%) at week 26 
Baseline Characteristics of EMMY trial participants stratified by treatment (N = 374)

Overall control of blood pressure and LDL-C levels in all patients at baseline
At randomization, baseline median (interquartile range [IQR]) NTproBNP level was 1365 pg/mL (773–2192), median Troponin T was 3003 ng/L (2047–4647), median creatinine kinase was 1648 U/L (1201–2452) and median estimated glomerular filtration rate (eGFR) was 92.0 ml/min/1.73m² (78.1-100.7). Echocardiographic parameters showed a median (IQR) LVEF of 48.0% (43.0-53.7) and a median E/E’ of 9.1 (7.5–10.7) At baseline inflammatory biomarkers were increased in both groups (within 72 h after presentation with AMI) and equally distributed in both groups with a median IL-6 (IQR) of 17.9 pg/mL (9.0-38.7), a median hsCRP of 18.9 mg/L (11.2–37.1), a median neutrophil rate of 7.9 × 10^9/L (6.2–10.1), a median leukocyte rate of 10.8 × 10^9/L (9.1–12.8), a median NLR of 0.74 (0.67–0.80), and a median PLR of 125.58 (97.14-171.82) 
Inflammatory markers at each visit and percentage change in markers over time

